Molecular Pathways in Cancers
This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient out...
Պահպանված է:
| Ձևաչափ: | Online |
|---|---|
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | ONIX_20220506_9783036536828_268 |
| Ցուցիչներ: |
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
| _version_ | 1869522845427564544 |
|---|---|
| collection | Directory of Open Access Books |
| description | This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes. |
| format | Online |
| id | doab-20.500.12854ir-81202 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-812022024-03-31T13:10:41Z Molecular Pathways in Cancers Cristóbal, Ion Rodríguez, Marta actin cytoskeletal reorganization breast cancer CD99 agonist EGFR dimerization endocytosis FAK dephosphorylation PTPN12 Rac1 RhoA tripeptide OMD PRELP tumor suppression gene bladder cancer initiation tight junction partial EMT tousled-like kinase (TLK) NIMA-related kinase 1 (NEK1) yes-associated protein 1 (YAP1) thioridazine (THD) MS-determined phosphopeptides human immunodeficiency virus type 1 epithelial cells carcinogenicity oxidative stress reactive oxygen species gp120 Tat Nef matrix protein p17 reverse transcriptase mitochondria metastasis OXPHOS cancer Warburg effect cancer therapeutics myeloproliferative neoplasms signaling pathways JAK2 CALR MPL TPOR DUSP1 MAPK Snail prostate cancer migration and invasion patient survival biomarkers pBRD4 SET PP2A prognosis triple negative breast cancer resistance anti-receptor therapy trastuzumab PI3K mTOR TAK-228 epigenetic methylation acetylation non-coding RNA small-cell lung cancer triple-negative breast cancer pancreatic ductal adenocarcinoma glioblastoma metastatic melanoma advanced ovarian cancer hepatocellular carcinoma immune evasion immunotherapy immune checkpoint inhibitors oncogenic signaling pathway molecular targeted agents genome epigenome tumor immune microenvironment ovarian cancer adaptive immunity innate immunity complement system cancer immunology tumor microenvironment splicing pathway luminal breast cancer BET inhibitors n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes. 2022-05-06T11:35:08Z 2022-05-06T11:35:08Z 2022 book ONIX_20220506_9783036536828_268 9783036536828 9783036536811 https://directory.doabooks.org/handle/20.500.12854/81202 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5234 https://mdpi.com/books/pdfview/book/5234 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3681-1 10.3390/books978-3-0365-3681-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036536828 9783036536811 284 Basel open access |
| spellingShingle | actin cytoskeletal reorganization breast cancer CD99 agonist EGFR dimerization endocytosis FAK dephosphorylation PTPN12 Rac1 RhoA tripeptide OMD PRELP tumor suppression gene bladder cancer initiation tight junction partial EMT tousled-like kinase (TLK) NIMA-related kinase 1 (NEK1) yes-associated protein 1 (YAP1) thioridazine (THD) MS-determined phosphopeptides human immunodeficiency virus type 1 epithelial cells carcinogenicity oxidative stress reactive oxygen species gp120 Tat Nef matrix protein p17 reverse transcriptase mitochondria metastasis OXPHOS cancer Warburg effect cancer therapeutics myeloproliferative neoplasms signaling pathways JAK2 CALR MPL TPOR DUSP1 MAPK Snail prostate cancer migration and invasion patient survival biomarkers pBRD4 SET PP2A prognosis triple negative breast cancer resistance anti-receptor therapy trastuzumab PI3K mTOR TAK-228 epigenetic methylation acetylation non-coding RNA small-cell lung cancer triple-negative breast cancer pancreatic ductal adenocarcinoma glioblastoma metastatic melanoma advanced ovarian cancer hepatocellular carcinoma immune evasion immunotherapy immune checkpoint inhibitors oncogenic signaling pathway molecular targeted agents genome epigenome tumor immune microenvironment ovarian cancer adaptive immunity innate immunity complement system cancer immunology tumor microenvironment splicing pathway luminal breast cancer BET inhibitors n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Molecular Pathways in Cancers |
| title | Molecular Pathways in Cancers |
| title_full | Molecular Pathways in Cancers |
| title_fullStr | Molecular Pathways in Cancers |
| title_full_unstemmed | Molecular Pathways in Cancers |
| title_short | Molecular Pathways in Cancers |
| title_sort | molecular pathways in cancers |
| topic | actin cytoskeletal reorganization breast cancer CD99 agonist EGFR dimerization endocytosis FAK dephosphorylation PTPN12 Rac1 RhoA tripeptide OMD PRELP tumor suppression gene bladder cancer initiation tight junction partial EMT tousled-like kinase (TLK) NIMA-related kinase 1 (NEK1) yes-associated protein 1 (YAP1) thioridazine (THD) MS-determined phosphopeptides human immunodeficiency virus type 1 epithelial cells carcinogenicity oxidative stress reactive oxygen species gp120 Tat Nef matrix protein p17 reverse transcriptase mitochondria metastasis OXPHOS cancer Warburg effect cancer therapeutics myeloproliferative neoplasms signaling pathways JAK2 CALR MPL TPOR DUSP1 MAPK Snail prostate cancer migration and invasion patient survival biomarkers pBRD4 SET PP2A prognosis triple negative breast cancer resistance anti-receptor therapy trastuzumab PI3K mTOR TAK-228 epigenetic methylation acetylation non-coding RNA small-cell lung cancer triple-negative breast cancer pancreatic ductal adenocarcinoma glioblastoma metastatic melanoma advanced ovarian cancer hepatocellular carcinoma immune evasion immunotherapy immune checkpoint inhibitors oncogenic signaling pathway molecular targeted agents genome epigenome tumor immune microenvironment ovarian cancer adaptive immunity innate immunity complement system cancer immunology tumor microenvironment splicing pathway luminal breast cancer BET inhibitors n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | actin cytoskeletal reorganization breast cancer CD99 agonist EGFR dimerization endocytosis FAK dephosphorylation PTPN12 Rac1 RhoA tripeptide OMD PRELP tumor suppression gene bladder cancer initiation tight junction partial EMT tousled-like kinase (TLK) NIMA-related kinase 1 (NEK1) yes-associated protein 1 (YAP1) thioridazine (THD) MS-determined phosphopeptides human immunodeficiency virus type 1 epithelial cells carcinogenicity oxidative stress reactive oxygen species gp120 Tat Nef matrix protein p17 reverse transcriptase mitochondria metastasis OXPHOS cancer Warburg effect cancer therapeutics myeloproliferative neoplasms signaling pathways JAK2 CALR MPL TPOR DUSP1 MAPK Snail prostate cancer migration and invasion patient survival biomarkers pBRD4 SET PP2A prognosis triple negative breast cancer resistance anti-receptor therapy trastuzumab PI3K mTOR TAK-228 epigenetic methylation acetylation non-coding RNA small-cell lung cancer triple-negative breast cancer pancreatic ductal adenocarcinoma glioblastoma metastatic melanoma advanced ovarian cancer hepatocellular carcinoma immune evasion immunotherapy immune checkpoint inhibitors oncogenic signaling pathway molecular targeted agents genome epigenome tumor immune microenvironment ovarian cancer adaptive immunity innate immunity complement system cancer immunology tumor microenvironment splicing pathway luminal breast cancer BET inhibitors n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20220506_9783036536828_268 |